445 related articles for article (PubMed ID: 22716133)
1. The yin and yang of cannabis-induced psychosis: the actions of Δ(9)-tetrahydrocannabinol and cannabidiol in rodent models of schizophrenia.
Arnold JC; Boucher AA; Karl T
Curr Pharm Des; 2012; 18(32):5113-30. PubMed ID: 22716133
[TBL] [Abstract][Full Text] [Related]
2. Medical use of cannabis. Cannabidiol: a new light for schizophrenia?
Deiana S
Drug Test Anal; 2013 Jan; 5(1):46-51. PubMed ID: 23109356
[TBL] [Abstract][Full Text] [Related]
3. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis.
Morgan CJ; Curran HV
Br J Psychiatry; 2008 Apr; 192(4):306-7. PubMed ID: 18378995
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol Counteracts the Psychotropic Side-Effects of Δ-9-Tetrahydrocannabinol in the Ventral Hippocampus through Bidirectional Control of ERK1-2 Phosphorylation.
Hudson R; Renard J; Norris C; Rushlow WJ; Laviolette SR
J Neurosci; 2019 Oct; 39(44):8762-8777. PubMed ID: 31570536
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ
Boggs DL; Nguyen JD; Morgenson D; Taffe MA; Ranganathan M
Neuropsychopharmacology; 2018 Jan; 43(1):142-154. PubMed ID: 28875990
[TBL] [Abstract][Full Text] [Related]
6. A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice.
Long LE; Chesworth R; Huang XF; McGregor IS; Arnold JC; Karl T
Int J Neuropsychopharmacol; 2010 Aug; 13(7):861-76. PubMed ID: 19785914
[TBL] [Abstract][Full Text] [Related]
7. Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts: A Naturalistic Controlled Study.
Sainz-Cort A; Jimenez-Garrido D; Muñoz-Marron E; Viejo-Sobera R; Heeroma J; Bouso JC
J Clin Psychopharmacol; 2021 Sep-Oct 01; 41(5):561-570. PubMed ID: 34412109
[TBL] [Abstract][Full Text] [Related]
8. The Yin and Yang of Cannabis: A Systematic Review of Human Neuroimaging Evidence of the Differential Effects of Δ
Gunasekera B; Davies C; Martin-Santos R; Bhattacharyya S
Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Jun; 6(6):636-645. PubMed ID: 33414100
[TBL] [Abstract][Full Text] [Related]
9. A randomised controlled trial of vaporised Δ
Solowij N; Broyd S; Greenwood LM; van Hell H; Martelozzo D; Rueb K; Todd J; Liu Z; Galettis P; Martin J; Murray R; Jones A; Michie PT; Croft R
Eur Arch Psychiatry Clin Neurosci; 2019 Feb; 269(1):17-35. PubMed ID: 30661105
[TBL] [Abstract][Full Text] [Related]
10. An assessment of concurrent cannabidiol and Δ⁹-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning.
Hempel BJ; Clasen MM; Nelson KH; Woloshchuk CJ; Riley AL
Exp Clin Psychopharmacol; 2018 Apr; 26(2):205-213. PubMed ID: 29648861
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of Medical Cannabis.
Amin MR; Ali DW
Adv Exp Med Biol; 2019; 1162():151-165. PubMed ID: 31332738
[TBL] [Abstract][Full Text] [Related]
12. Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis.
Mielnik CA; Li CK; Ramsey AJ; Salahpour A; Burnham WM; Ross RA
Cannabis Cannabinoid Res; 2024 Feb; 9(1):174-187. PubMed ID: 36251462
[No Abstract] [Full Text] [Related]
13. Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.
Morgan CJA; Freeman TP; Hindocha C; Schafer G; Gardner C; Curran HV
Transl Psychiatry; 2018 Sep; 8(1):181. PubMed ID: 30185793
[TBL] [Abstract][Full Text] [Related]
14. How does cannabidiol (CBD) influence the acute effects of delta-9-tetrahydrocannabinol (THC) in humans? A systematic review.
Freeman AM; Petrilli K; Lees R; Hindocha C; Mokrysz C; Curran HV; Saunders R; Freeman TP
Neurosci Biobehav Rev; 2019 Dec; 107():696-712. PubMed ID: 31580839
[TBL] [Abstract][Full Text] [Related]
15. What is the mechanism whereby cannabis use increases risk of psychosis?
Luzi S; Morrison PD; Powell J; di Forti M; Murray RM
Neurotox Res; 2008 Oct; 14(2-3):105-12. PubMed ID: 19073418
[TBL] [Abstract][Full Text] [Related]
16. Sub-chronic impact of cannabinoids in street cannabis on cognition, psychotic-like symptoms and psychological well-being.
Morgan CJ; Gardener C; Schafer G; Swan S; Demarchi C; Freeman TP; Warrington P; Rupasinghe I; Ramoutar A; Tan N; Wingham G; Lewis S; Curran HV
Psychol Med; 2012 Feb; 42(2):391-400. PubMed ID: 21798112
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity.
Juckel G; Roser P; Nadulski T; Stadelmann AM; Gallinat J
Schizophr Res; 2007 Dec; 97(1-3):109-17. PubMed ID: 17884351
[TBL] [Abstract][Full Text] [Related]
18. Acute effects of cannabinoids on addiction endophenotypes are moderated by genes encoding the CB1 receptor and FAAH enzyme.
Hindocha C; Freeman TP; Schafer G; Gardner C; Bloomfield MAP; Bramon E; Morgan CJA; Curran HV
Addict Biol; 2020 May; 25(3):e12762. PubMed ID: 31013550
[TBL] [Abstract][Full Text] [Related]
19. Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.
Dos Santos RG; Hallak JEC; Crippa JAS
Adv Exp Med Biol; 2021; 1264():29-45. PubMed ID: 33332002
[TBL] [Abstract][Full Text] [Related]
20. Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.
Vann RE; Gamage TF; Warner JA; Marshall EM; Taylor NL; Martin BR; Wiley JL
Drug Alcohol Depend; 2008 Apr; 94(1-3):191-8. PubMed ID: 18206320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]